ENSCW · Ensysce Biosciences, Inc.

Summary

Ensysce Biosciences, Inc. filed a Certificate of Correction on March 18, 2026, with the State of Delaware to the Certificate of Designation of Series B Preferred Stock, correcting a scrivener’s error in Section 4(d)(ii) regarding Principal Market Regulation and the Exchange Cap. The full corrected text is provided in Exhibit 3.1.

Key takeaways

• Filed Certificate of Correction on March 18, 2026, to fix scrivener’s error in Section 4(d)(ii) of Series B Preferred Stock Certificate of Designation.
• Corrected provision addresses Principal Market Regulation, Exchange Cap under NASDAQ Listing Rule 5635(d), and allocation rules for Holders.